ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Cancer
Endometrial Cancer
Ovarian Cancer
Neoplasm Metastasis

Triple Negative Breast Cancer trials near Milano, Lombardia, ITA:

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel (ATRiBRAVE)

This study will evaluate the efficacy and safety of ceralasertib followed by durvalumab plus nab-paclitaxel in 37 patients with TNBC, whose tumor...

Enrolling
Triple Negative Breast Cancer Metastatic
Drug: Ceralasertib
Drug: Durvalumab

Phase 2

IFOM ETS - The AIRC Institute of Molecular Oncology

BERGAMO, Bergamo, Italy and 5 other locations

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Milano, Italy and 197 other locations

Locations recently updated

and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen rec...

Enrolling
Breast Neoplasms
Drug: Paclitaxel
Drug: Iza-bren

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Novara, Italy and 288 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Milan, Italy and 374 other locations

for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...

Active, not recruiting
Breast Cancer
Drug: Tobemstomig
Drug: Nab-Paclitaxel

Phase 2

Roche
Roche

Milan, Lombardy, Italy and 39 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Milan, Italy and 506 other locations

platinum-resistant ovarian cancer. This cohort will be made up of 20 evaluable patients, 10 per arm....

Enrolling
Epithelial Ovarian Cancer
Endometrioid Ovarian Cancer
Drug: NI-1801 in combination with anti-PD1 (Pembrolizumab)
Drug: Biological NI-1801

Phase 1

Light Chain Bioscience

Milano, Italy and 6 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Milan, Italy and 227 other locations

Locations recently updated

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer...

Enrolling
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Paclitaxel

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Novara, Italy and 210 other locations

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Active, not recruiting
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Milan, Italy and 275 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems